Skip to navigationSkip to content
BizHanKook BizHanKook

OCI Holdings Completes Sale of US Bio-Investment Subsidiary to Bukwang Pharm

[BizHanKook]  It has been confirmed that OCI Holdings has sold its US bio-investment entity, OCI Investments Corp., to its subsidiary, Bukwang Pharm. With the bio-investment firm previously held by OCI Group through an overseas affiliate now incorporated into Bukwang Pharm, the ownership structure of the group’s bio-investment assets has shifted. While the deal is estimated to be worth approximately 7 billion KRW, the exact sale price and valuation method have not been disclosed.

Bukwang Pharm plans to unveil its plans for OCI Investments, which it recently acquired from OCI Enterprises, at its upcoming R&D Day on the 24th. Photo by Reporter Choi Young-chan

An OCI Holdings official told BizHankook on the 20th, "The parties involved in the transaction were OCI Enterprises and Bukwang Pharm, and the sale has now been completed," adding, "However, it is difficult to disclose the precise sale amount and the pricing methodology."

OCI Investments was established by OCI Holdings in 2019. Prior to the sale, it was wholly owned by OCI Enterprises Inc., a US-based subsidiary 100% owned by OCI Holdings. OCI Investments also holds a 100% stake in two other investment entities: OCI Bio Investments LLC and OCI Bio Investments II LLC.

According to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART), Bukwang Pharm’s board of directors approved the "acquisition of OCI Investments" on July 21. However, the Q3 report submitted by OCI Holdings on the 13th still listed OCI Enterprises as the 100% owner of OCI Investments as of the end of September. Although the existing ownership structure remained in place until that time despite the approval, the inter-affiliate sale has since been finalized.

OCI Investments Manages Overseas Bio-Company Investments

The sale price of OCI Investments is estimated to be around 7 billion KRW. A review of OCI Holdings' Q3 report reveals that the company decided to sell financial assets measured at fair value through profit or loss held by OCI Enterprises, reclassifying approximately 7.025 billion KRW as assets held for sale.

The OCI Holdings official explained, "It is correct that the asset held for sale is OCI Investments," adding that "the amount may fluctuate due to exchange rate differences." As of the end of 2025, the total assets of OCI Investments, which is 100% owned by OCI Enterprises, amounted to 7.499 billion KRW based on separate financial statements.

OCI Investments counts OCI Bio Investments LLC and OCI Bio Investments II LLC as its wholly-owned subsidiaries. As of the end of last year, the total assets of OCI Bio Investments LLC were 512 million KRW, while those of OCI Bio Investments II LLC were 6.987 billion KRW.

OCI Investments has been responsible for OCI Group's overseas bio-company investments. OCI Holdings began its foray into the bio sector through the Synergy Healthcare Venture Fund in 2018, and established a local US entity the following year, which invested in companies such as Adicet Bio (based in the US) and Nucleix (based in Israel).

Adicet Bio is a developer of immune cell therapies, while Nucleix is developing liquid biopsy-based early cancer diagnostic technologies.

However, the specific investment stakes currently held by OCI Investments and the status of investment recovery have not been verified. An OCI Holdings representative stated, "The financial status of OCI Investments and the investment scale of its existing portfolio companies are not subject to public disclosure."

OCI Holdings has distanced itself from the interpretation that this transaction is a move to consolidate overseas bio-investment operations under Bukwang Pharm. Photo by Reporter Choi Young-chan

OCI Holdings Says "Strategic Choice," Denies Plans for Further Stake Increases in Bukwang Pharm

This transaction has sparked interest in whether OCI Group intends to consolidate its pharmaceutical and bio-business under Bukwang Pharm. Since becoming the largest shareholder of Bukwang Pharm in 2022, OCI Holdings has pursued a strategy of linking its existing bio-investment capabilities with Bukwang Pharm’s new drug development business.

In July last year, OCI participated in Bukwang Pharm's capital increase, raising its stake from 11.32% to 17.11%. Bukwang Pharm also expanded its business by acquiring a 75.14% stake in the rehabilitated company Korea Union Pharm this past May. Korea Union Pharm has since changed its name to Bukwang Unipharma.

However, OCI Holdings has distanced itself from the interpretation that this deal is a measure to centralize overseas bio-investments under Bukwang Pharm. "Rather than a concept of transferring the role of overseas bio-investment within the OCI Group to Bukwang Pharm, this is a sale between affiliates based on a strategic choice," the OCI Holdings official explained.

The company also stated that the move is separate from any plans to increase its stake in Bukwang Pharm. Upon transitioning to a holding company structure in 2023, OCI Holdings was required under the Fair Trade Act to increase its stake in the listed subsidiary Bukwang Pharm to 30%. Although it was initially expected to meet this requirement by September of last year, the Korea Fair Trade Commission granted a two-year grace period, extending the deadline to September 2027.

OCI Holdings stated, "The sale of OCI Investments and the plan to acquire additional shares of Bukwang Pharm are unrelated matters, and no direction for the share acquisition has been decided yet."

Meanwhile, the acquiring entity, Bukwang Pharm, plans to address the transaction on the 24th. When asked about the background of the acquisition and future plans, a Bukwang Pharm official replied, "We will explain it during our R&D Day on the 24th."

Choi Young-chan

I cover the pharmaceutical and biotech sectors. I am committed to listening closely, studying continuously, and delivering accurate reporting.

chan111@bizhankook.com
Copyright © BizHanKook. All rights reserved.